Congratulations to Joseph D’Orazio, MD, FAAEM, FACMT, FASAM, FCPP, Addiction Medicine Specialist at Cooper, and Rachel Haroz, MD, FAACT, Medical Director of the Cooper Center for Healing and Division Head of Toxicology and Addiction Medicine, on their publication of “Xylazine Adulteration of the Heroin-Fentanyl Drug Supply: A Narrative Review” in the Annals of Internal Medicine. Together with colleagues, Drs. D’Orazio and Haroz conducted research that looks at the current impact of xylazine in the drug supply, including caring for patients experiencing acute overdose, withdrawal, and associated wounds.
Dr. D’Orazio, lead author on the piece, is featured in the following interviews:
Growing ‘Tranq’ threat poses challenges for PCPs Medscape
Animal tranquiliser added to opioids causing ‘steep increase’ in deaths
The Guardian
What to know about xylazine as contamination in illicit drug supply surges
Audacy